Trial Profile
Efficacy and safety of first-line therapy with chlorambucil, rituximab and lenalidomide (Revlimid®) (CR2 ) in elderly patients and young frail patients with advanced Chronic Lymphocytic Leukemia (CLL): a phase I/II trial
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 Apr 2020
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Chlorambucil; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 21 Apr 2020 Trial design presented in Hemato-Oncologie voor Volwassenen Nederland foundation.
- 21 Apr 2020 Status changed from planning to completed according to Hemato-Oncologie voor Volwassenen Nederland foundation.
- 15 Sep 2011 New trial record